Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Journal of Gastrointestinal Cancer|June 4, 2026
Who Truly Benefits from Anti-EGFR Rechallenge in Metastatic Colorectal Cancer? From Clinical Enrichment to ctDNA-Guided Molecular HyperselectionTamotsu Sagawa, Koshi FujikawaJournal of Gastrointestinal Cancer|June 22, 2026
Positioning Zolbetuximab in HER2-Negative Advanced Gastric Cancer: A Practical Framework for Treatment Selection in the ICI EraTamotsu Sagawa, Koshi FujikawaJournal of Gastrointestinal Cancer|June 4, 2026
Beyond Sidedness: DNA Methylation as a Biomarker to Refine Anti-EGFR Treatment Selection in RAS/BRAF Wild-type Metastatic Colorectal CancerTamotsu Sagawa, Hiroyuki Nagashima, Koshi FujikawaJournal of Gastrointestinal Cancer|July 9, 2026
Treatment Selection Beyond Second Line in Metastatic Colorectal Cancer: Practical Sequencing of Cytotoxic Salvage Therapy, Anti-angiogenic Agents, Rechallenge Strategies, and Biomarker-Guided TreatmentsTamotsu Sagawa, Hiroyuki Nagashima, Koshi FujikawaJournal of Gastrointestinal Cancer|July 9, 2026
Optimal First-Line Immunotherapy for MSI-H/dMMR Metastatic Colorectal Cancer: Evidence, Gaps, and Clinical Decision-MakingTamotsu Sagawa, Hiroyuki Nagashima, Koshi FujikawaJournal of Cellular Physiology|October 30, 2003
Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKC betaYihong Wang, Sergey Pampou, Koshi Fujikawa, et al.Journal of Cellular Biochemistry|April 23, 2002
NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: a potential mechanism for Tie2 regulation during hypoxiaRial A Christensen, Koshi Fujikawa, Rebecca Madore, et al.International Journal of Clinical Oncology|April 30, 2026
Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerMasahiro Hirakawa, Tamotsu Sagawa, Yutaka Okagawa, et al.Journal of Gastrointestinal Cancer|June 26, 2026
Clinical Outcomes of Second-Line FOLFIRI Plus Ramucirumab According to Prior Biologic Exposure in Metastatic Colorectal Cancer: A Retrospective Comparison of Prior Bevacizumab and Prior Anti-EGFR CohortsTamotsu Sagawa, Masahiro Hirakawa, Shutaro Oiwa, et al.Cancer Chemotherapy and Pharmacology|September 1, 2018
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxaneHironaga Satake, Tamotsu Sagawa, Koshi Fujikawa, et al.Pageof 4